Prescription Drug Abuse Prevention and Treatment Act of 2013

The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348

Client expense: $520,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)

Public Law 111-152, Health Care and Education Reconciliation Act of 2010, Implementation of addiction treatment issues. Public Law 110-343, Emergency Economic Stabilization Act of 2008, Regulations implementation, Mental health and addiction parity Public Law 111-148, Patient Protection and Affordable Care Act, Implementation of addiction treatment issues. Prescription Drug abuse issues. S.2092/H.R.4288, Opioid Overdose Reduction Act of 2014, Access to Naloxone S.348/H.R.672, Prescription Drug Abuse Prevention and Treatment Act of 2013, Prescription drug abuse related issues S.2504, A bill to address prescription opioid and heroin abuse, generally S.2645, TREAT Act, Addiction treatment and recovery issues; 100 patient limit for buprenorphine prescribers S.2839, Comprehensive Addiction and Recovery Act of 2014, Prescription opioid abuse and heroin use treatment issues Addition to #17 below: Center for Substance Abuse Treatment (CSAT)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Pediatric Subspeciality and Mental Health Workforce Reauthorization Act of 2013 (HR 1827) Helping Families in Mental Health Crisis Act (HR 3717) Strengthening Mental Health in Our Communities Act of 2014 (HR 4574) Excellence in Mental Health Act (S 264, HR 1263) Community-Based Mental Health Infrastructure Improvements Act (S 265) Mental Health First Act of 2013 (HR 274, S 153) Prescription Drug Abuse Prevention and Treatment Act of 2013 (HR 672) Healthy Families Act (S 631) Native American Psychiatric and Mental Health Care Improvement Act (HR 2037) AGE-IN Act (S 1259) Garrett Lee Smith Memorial Act Reauthorization of 2013 (HR 2734) Behavioral Health Information Technology Act of 2013 (HR 2957, S 1517) Telehealth Modernization Act of 2013 (HR 3750) Youth Mental Health Research Act (HR 4170) To amend title XVIII of the Social Security Act to provide for treatment of clinical psychologists as physicians for purposes of furnishing clinical psychologist services under the Medicare Program (HR 794, S 1064) House & Senate HHS Appropriation Bills for FY15 (Pediatric Subspecialty Loan Repayment, BRAIN Initiative, National Mental Health Policy Laboratory, the Garrett Lee Smith Program, Children's Health GME funding) Autism Cares Act (HR 4631, S 2449) Caring for America's Hero's Act (HR 4656, S 2276) Health plan network adequacy for child and adolescent psychiatrists Funding for greater youth involvement to erase stigma

Client expense: $43,400 · Firm income: Not reported

H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348

Client expense: $390,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 348/H.R. 672, Prescription Drug Abuse Prevention and Treatment Act- A bill to provide for increased Federal oversight of prescription opioid treatment and assistance to States in reducing opioid abuse, diversion, and deaths. (entire bill)

Client expense: $350,000 · Firm income: Not reported

Government targets: Federal Emergency Management Agency (FEMA), Federal Reserve System, HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Office of Management & Budget (OMB), SENATE, Treasury, Dept of

Public Law 111-152, Health Care and Education Reconciliation Act of 2010, Implementation of addiction treatment issues. Public Law 110-343, Emergency Economic Stabilization Act of 2008, Regulations implementation, Mental health and addiction parity Public Law 111-148, Patient Protection and Affordable Care Act, Implementation of addiction treatment issues. Prescription Drug abuse issues. S.2092/H.R.4288, Opioid Overdose Reduction Act of 2014, Access to Naloxone 100 patient limit for buprenorphine prescribers S.348/H.R.672, Prescription Drug Abuse Prevention and Treatment Act of 2013, Prescription drug abuse related issues S.2504, A bill to address prescription opioid and heroin abuse, generally S.2645, TREAT Act, Addiction treatment and recovery issues S.2839, Comprehensive Addiction and Recovery Act of 2014, Prescription opioid abuse and heroin use treatment issues Addition to #17 below: Center for Substance Abuse Treatment (CSAT)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Pediatric Subspeciality and Mental Health Workforce Reauthorization Act of 2013 (HR 1827) Helping Families in Mental Health Crisis Act (HR 3717) Strengthening Mental Health in Our Communities Act of 2014 (HR 4574) Excellence in Mental Health Act (S 264, HR 1263)Community-Based Mental Health Infrastructure Improvements Act (S 265) Mental Health First Act of 2013 (HR 274, S 153) Prescription Drug Abuse Prevention and Treatment Act of 2013 (HR 672) Healthy Families Act (S 631) Native American Psychiatric and Mental Health Care Improvement Act (HR 2037) AGE-IN Act (S 1259) Garrett Lee Smith Memorial Act Reauthorization of 2013 (HR 2734) Behavioral Health Information Technology Act of 2013 (HR 2957, S 1517) Telehealth Modernization Act of 2013 (HR 3750) Youth Mental Health Research Act (HR 4170) To amend title XVIII of the Social Security Act to provide for treatment of clinical psychologists as physicians for purposes of furnishing clinical psychologist services under the Medicare Program (HR 794, S 1064) House & Senate HHS Appropriation Bills for FY15 (Pediatric Subspecialty Loan Repayment, BRAIN Initiative, National Mental Health Policy Laboratory, the Garrett Lee Smith Program, Chidlren's Health GME funding) Autism Cares Act (HR 4631, S 2449) Caring for America's Hero's Act (HR 4656, S 2276) Health plan network adequacy for child and adolescent psychiatrists

Client expense: $74,200 · Firm income: Not reported

H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348

Client expense: $680,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 348/H.R. 672, Prescription Drug Abuse Prevention and Treatment Act- A bill to provide for increased Federal oversight of prescription opioid treatment and assistance to States in reducing opioid abuse, diversion, and deaths. (entire bill)

Client expense: $380,000 · Firm income: Not reported

Government targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Office of Management & Budget (OMB), SENATE, Treasury, Dept of

Pediatric Subspeciality and Mental Health Workforce Reauthorization Act of 2013 (HR 1827) Helping Families in Mental Health Crisis Act (HR 3717) Strengthening Mental Health in Our Communities Act of 2014 (HR 4574) Excellence in Mental Health Act (S 264, HR 1263)Community-Based Mental Health Infrastructure Improvements Act (S 265) Mental Health First Act of 2013 (HR 274, S 153) Prescription Drug Abuse Prevention and Treatment Act of 2013 (HR 672) Healthy Families Act (S 631) Native American Psychiatric and Mental Health Care Improvement Act (HR 2037) AGE-IN Act (S 1259) Garrett Lee Smith Memorial Act Reauthorization of 2013 (HR 2734) Behavioral Health Information Technology Act of 2013 (HR 2957, S 1517) Telehealth Modernization Act of 2013 (HR 3750) Youth Mental Health Research Act (HR 4170) To amend title XVIII of the Social Security Act to provide for treatment of clinical psychologists as physicians for purposes of furnishing clinical psychologist services under the Medicare Program (HR 794, S 1064) House & Senate HHS Appropriation Bills for FY15 (Pediatric Subspecialty Loan Repayment, BRAIN Initiative, National Mental Health Policy Laboratory, the Garrett Lee Smith Program, Chidlren's Health GME funding)

Client expense: $89,300 · Firm income: Not reported

Public Law 111-152, Health Care and Education Reconciliation Act of 2010, Implementation of addiction treatment issues. Public Law 110-343, Emergency Economic Stabilization Act of 2008, Regulations implementation, Mental health and addiction parity Public Law 111-148, Patient Protection and Affordable Care Act, Implementation of addiction treatment issues. Prescription Drug abuse issues. S.2092/H.R.4288, Opioid Overdose Reduction Act of 2014, Access to Naloxone 100 patient limit for buprenorphine prescribers S.348/H.R.672, Prescription Drug Abuse Prevention and Treatment Act of 2013, Prescription drug abuse related issues S.2504, A bill to address prescription opioid and heroin abuse, Prescription drug abuse related issues Addition to #17 below: Center for Substance Abuse Treatment (CSAT)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations

Client expense: Not reported · Firm income: $120,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348

Client expense: $420,000 · Firm income: Not reported

Government targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE

Safe Prescribing Act (HR 1285/S 621) Stop Oxy Abuse Act (HR 1366) Prescription Drug Abuse Prevention and Treatment Act (HR 672/S 348) Access to Substance Abuse Treatment Act of 2013 (HR 2130)

Client expense: $26,518 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Pediatric Subspeciality and Mental Health Workforce Reauthorization Act of 2013 (HR 1827) Helping Families in Mental Health Crisis Act (HR 3717) Excellence in Mental Health Act (S 264, HR 1263) Community-Based Mental Health Infrastructure Improvements Act (S 265)Mental Health First Act of 2013 (HR 274, S 153) Prescription Drug Abuse Prevention and Treatment Act of 2013 (HR 672) Healthy Families Act (S 631) Native American Psychiatric and Mental Health Care Improvement Act (HR 2037) AGE-IN Act (S 1259) Garrett Lee Smith Memorial Act Reauthorization of 2013 (HR 2734) Behavioral Health Information Technology Act of 2013 (HR 2957, S 1517) Telehealth Modernization Act of 2013 (HR 3750) Youth Mental Health Research Act (HR 4170) To amend title XVIII of the Social Security Act to provide for treatment of clinical psychologists as physicians for purposes of furnishing clinical psychologist services under the Medicare Program (HR 794, S 1064)

Client expense: $32,330 · Firm income: Not reported

S. 348/H.R. 672, Prescription Drug Abuse Prevention and Treatment Act

Client expense: $260,000 · Firm income: Not reported

Government targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Office of Management & Budget (OMB), SENATE, Treasury, Dept of

The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348

Client expense: $730,000 · Firm income: Not reported

Government targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE

H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 348/H.R. 672: Prescription Drug Abuse Prevention and Treatment Act

Client expense: $330,000 · Firm income: Not reported

Government targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Office of Management & Budget (OMB), SENATE, Treasury, Dept of

HR.672 Prescription Drug Abuse Prevention and Treatment Act of 2013 S. 348 Prescription Drug Abuse Prevention and Treatment Act of 2013 Prescription drug abuse S. 1365 Part D Beneficiary Appeals Fairness ActSpecialty drug costs

Client expense: $200,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

HR.672 Prescription Drug Abuse Prevention and Treatment Act of 2013 S. 348 Prescription Drug Abuse Prevention and Treatment Act of 2013 Prescription drug abuse S. 1365 Part D Beneficiary Appeals Fairness Actspecialty drug costs

Client expense: $200,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

HR.672 Prescription Drug Abuse Prevention and Treatment Act of 2013 S. 348 Prescription Drug Abuse Prevention and Treatment Act of 2013 Prescription drug abuse S. 1365 Part D Beneficiary Appeals Fairness Actspecialty drug costs

Client expense: $200,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348

Client expense: $790,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 348/H.R. 672: Prescription Drug Abuse Prevention and Treatment Act

Client expense: $290,000 · Firm income: Not reported

Government targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Office of Management & Budget (OMB), SENATE, Treasury, Dept of

H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Safe Prescribing Act (HR 1285/S 621) Stop Oxy Abuse Act (HR 1366) Prescription Drug Abuse Prevention and Treatment Act (HR 672/S 348) Access to Substance Abuse Treatment Act of 2013 (HR 2130)

Client expense: $29,680 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Opioid and prescription drug abuse - HR 672, Prescription Drug Abuse Prevention and Treatment Act of 2013; S 348, Prescription Drug Abuse Prevention and Treatment Act of 2013.

Client expense: Not reported · Firm income: $100,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348

Client expense: $310,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 348/H.R. 672: Prescription Drug Abuse Prevention and Treatment Act

Client expense: $290,000 · Firm income: Not reported

Government targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), SENATE, Treasury, Dept of

Safe Prescribing Act (HR 1285/S 621) Stop Oxy Abuse Act (HR 1366) Prescription Drug Abuse Prevention and Treatment Act (HR 672/S 348) Access to Substance Abuse Treatment Act of 2013 (HR 2130)

Client expense: $124,160 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348

Client expense: $441,590 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE

S. 348/H.R. 672: Prescription Drug Abuse Prevention and Treatment Act

Client expense: $230,000 · Firm income: Not reported

Government targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), SENATE, Treasury, Dept of

Safe Prescribing Act (HR 1285/S 621) Stop Oxy Abuse Act (HR 1366) Prescription Drug Abuse Prevention and Treatment Act (HR 672/S 348)

Client expense: $27,073 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

Excellence in Mental Health Act (S.264/H.R. 1263), all provisions related to expanding access to mental health and addictions care by supporting FQCBHCs in treating all individuals regardless of their ability to pay, with a comprehensive array of outpatient behavioral health servicesMental Health in Schools Act (S. 195/H.R. 628), all provisions related to revising community children and violence program to assist local communities and schools in applying a public health approach to mental health services Mental Health First Aid Act of 2013 (S. 153/H.R. 274), all provisions related to authorizing a demonstration program to train college faculty and staff in Mental Health First Aid, a community education program that helps people identify, understand, and respond to signs of mental illnesses and addictions and deal with psychiatric crises Justice and Mental Health Collaboration Act of 2013 (S. 162/H.R. 401), all provisions related to amending the Mentally Ill Offender Treatment and Crime Reduction Act of 2004 to expand the assistance provided under such Act, and reauthorize appropriations for FY2015-FY2019. Garrett Lee Smith Memorial Act Reauthorization of 2013 (S. 116), all provisions related to amending the Public Health Service Act to reauthorize and revise a research, training, and technical assistance resource center to prevent suicides (the Suicide Prevention Resource Center), expanding the program's focus from youth suicides to suicides among all ages, and repealing authority for grants to establish research, training, and technical assistance centers related to mental health, substance abuse and the justice system. Prescription Drug Abuse Prevention and Treatment Act of 2013 (S. 348/H.R. 672), all provisions related to amending the Public Health Service Act to direct the Administrator of the Substance Abuse and Mental Health Services Administration to award grants to states and nonprofit entities for consumer education about opioid abuse, including methadone abuse. NICS Reporting Improvement Act of 2013 (S. 480), all provisions related to improving the effectiveness of the National Instant Criminal Background Check System by clarifying reporting requirements related to adjudications of mental incompetency, and for other purposes.